Pfizer (PFIZER)

FairStock Score: 61/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look for a business that earns high returns on capital and carries little debt. Pfizer India ticks those boxes: ROE 20.24%, ROCE 21.62%, and debt/equity just 0.02. Piotroski F-Score 8/9 and Altman Z-Score 4.78 tell me the balance sheet is strong and accounting quality is good. Latest quarter sales were ₹645 Cr and net profit ₹142 Cr; free cash flow was ₹159 Cr. Promoter holding 63.92% gives skin in the game, and dividend yield 1.54% adds a modest cash return. But growth is the rub. Five-year revenue CAGR is only 2.39%, while recent sales and profit growth are 8.30% and 6.60%. That is not a fast compounder. At ₹4,874.80 and market cap ₹22,301 Cr, the market pays P/E 30.30 and P/B 5.31 for this steady profile. The Graham Number is ₹1,968.31, leaving a margin of safety of -157.18%, meaning the price is far above conservative asset-earnings value. A DCF intrinsic value of ₹6,885.68 offers a different, more optimistic view, and PEG 1.38 is not outrageous if growth improves. Still, with five-year CAGR so low, I would demand either a better price or clearer growth acceleration. The negative EV/EBITDA figure is unusual and likely distorts the picture, so I lean on ROE, ROCE, debt, and cash flow. This is a quality stalwart, not a bargain. I would watch it, not chase it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer